Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant mFOLFIRINOX or Gemcitabine/Nab-paclitaxel for Borderline Resectable Pancreatic Cancer
NCT04452461Phase 2Recruiting
- Sponsor
- Hamilton Health Sciences
- Start
- Mar 2021
- Primary completion
- Dec 2025
- Modality
- Polymer-based Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nab-paclitaxel, gemcitabine, oxaliplatin, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, fluorouracil and 1 more in pancreatic adenocarcinoma (PDAC), sponsored by Hamilton Health Sciences. Primary endpoints: Proportion of patients eligible enrolled at 18 months and Proportion of patients who complete the protocol at 18 months. Started Mar 2021; status: recruiting.
02
Drugs
nab-paclitaxelgemcitabineoxaliplatinirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabfluorouracil
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04452461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04452461.